HAEMONETICS CORP 4
4 · HAEMONETICS CORP · Filed Oct 29, 2013
Insider Transaction Report
Form 4
White Jonathan
VP Research and Development
Transactions
- Disposition to Issuer
Common Stock
2013-10-28$39.55/sh−329$13,013→ 27,473 total - Disposition to Issuer
Common Stock
2013-10-28$39.55/sh−298$11,786→ 27,175 total - Disposition to Issuer
Common Stock
2013-10-28$39.55/sh−129$5,102→ 27,046 total - Award
Non-Qualified Stock Option (right to buy)
2013-10-23+28,523→ 28,523 totalExercise: $41.66From: 2014-10-23Exp: 2019-10-23→ Common Stock (28,523 underlying)
Holdings
- 25,000
Performance Shares
Exercise: $0.00From: 2017-03-31Exp: 2017-12-31→ Common Stock (25,000 underlying) - 35,282
Non-Qualified Stock Option (right to buy)
Exercise: $30.02From: 2010-01-28Exp: 2016-01-28→ Common Stock (35,282 underlying) - 35,130
Non-Qualified Stock Option (right to buy)
Exercise: $30.67From: 2012-10-25Exp: 2018-10-25→ Common Stock (35,130 underlying) - 27,948
Non-Qualified Stock Option (right to buy)
Exercise: $33.92From: 2012-07-20Exp: 2018-07-20→ Common Stock (27,948 underlying) - 32,192
Non-Qualified Stock Option (right to buy)
Exercise: $39.05From: 2013-10-24Exp: 2019-10-24→ Common Stock (32,192 underlying) - 24,484
Non-Qualified Stock Option (right to buy)
Exercise: $26.47From: 2010-10-27Exp: 2016-10-27→ Common Stock (24,484 underlying) - 30,776
Non-Qualified Stock Option (right to buy)
Exercise: $27.50From: 2011-10-27Exp: 2017-10-27→ Common Stock (30,776 underlying)
Footnotes (3)
- [F1]Pursuant to a 10b5-1 Plan to cover tax liability for released shares.
- [F2]Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
- [F3]Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).